On May 7, 2025, MetaVia Inc. announced data from its Phase 2a clinical trial showing the benefits of DA-1241 for metabolic dysfunction-associated steatosis, presented at a major conference in Amsterdam from May 7-10, 2025.
AI Assistant
METAVIA INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.